• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

    41.06 +2.01 (+5.15%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 788,349
    Open 39.36
    Bid (Size) 41.06 (300)
    Ask (Size) 41.50 (100)
    Prev. Close 39.05
    Today's Range 38.86 - 41.15
    52wk Range 19.72 - 40.30
    Shares Outstanding 66,344,236
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss ↗
    Celldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the... 
    Via MarketBeat
    News headline image
    Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +52.0%
    +52.0%
    1 Month
    +8.2%
    +8.2%
    3 Month
    +21.3%
    +21.3%
    6 Month
    +63.1%
    +63.1%
    1 Year
    +88.3%
    +88.3%

    More News

    Read More
    News headline image
    Celldex Announces Planned Transition of Chief Financial Officer
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
    Via InvestorPlace
    Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup ↗
    Via Chartmill
    News headline image
    Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Celldex Reports First Quarter Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex to Present at Upcoming Investor Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Announces Pricing of $300 Million Public Offering of Common Stock
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Announces Proposed Public Offering of Common Stock
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
    Via The Motley Fool
    News headline image
    Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗
    Via Stocktwits
    Topics Earnings
    News headline image
    Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
    Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
    The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
    What is the current price of Celldex Therapeutics, Inc. - Common Stock?
    The current price of Celldex Therapeutics, Inc. - Common Stock is 41.06
    When was Celldex Therapeutics, Inc. - Common Stock last traded?
    The last trade of Celldex Therapeutics, Inc. - Common Stock was at 08/05/26 04:00 PM ET
    What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
    The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 2.72B
    How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
    Celldex Therapeutics, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.